Status:
RECRUITING
Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
Lead Sponsor:
Beijing Chao Yang Hospital
Conditions:
Acute Respiratory Distress Syndrome
Extracorporeal Membrane Oxygenation
Eligibility:
All Genders
18-75 years
Brief Summary
Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a salvage treatment for severe acute respiratory distress syndrome (ARDS). With the large-scale implementation of VV-ECMO in critical care m...
Eligibility Criteria
Inclusion
- Meet the diagnostic criteria of Berlin's definition for ARDS;
- Receiving VV-ECMO support.
Exclusion
- Patients had been on high pressure (Ppeak \>35 cm H2O) and a high fraction of inspired oxygen (FiO2\>0.8) ventilation for \>7 days;
- Patients had a contraindication to heparinization;
- Patients had an irreversible neurological injury;
- Patients had severe chronic lung disease with life expectancy \<6 months.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06062212
Start Date
October 1 2023
End Date
December 31 2025
Last Update
July 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Chao-Yang Hospital
Beijing, Beijing Municipality, China, 100020